xii Introduction –– Dextroamphetamine preparation for ADHD for ages 3 years and older. Amphetamine extended-release orally disintegrating tablet for ADHD for ages 6 years and older. Serotonin norepinephrine reuptake inhibitor (SNRI) for generalized anxiety disorder for ages 7 years and older. Second generation antipsychotic for schizophrenia for ages 13 years and older. ■■ The FDA added “long-term suppression of growth” to Warnings and Precautions for stimulant medications. ■■ Weight gain and secondary metabolic changes from antipsychotic medications became more prominent concerns as more data emerged regarding monitoring and treatment. ■■ Commercial marketing increased for genetic testing for pharmaco‑ kinetics and pharmacodynamics of psychiatric medications in pediatric primary care. ■■ Articles were published questioning the efficacy of medications for ADHD and depression other articles refuted these claims. ■■ The AAP released several new and relevant clinical reports, technical reports, and policy statements (see Appendix B). ■■ The AAP published Mental Health Care of Children and Adolescents: A Guide for Primary Care Clinicians, with a chapter on psychopharmacology based on the conceptual framework and recommendations described in this book. Target Audience This book is written for pediatric primary care clinicians (PCCs) who care for children and adolescents with common psychiatric disorders in their outpatient practices and who prescribe and monitor medications, including ■■ Primary care pediatricians ■■ Family physicians ■■ Pediatric physician assistants ■■ Pediatric, psychiatric, and family nurse practitioners Secondary audiences include specialists who provide consultation to pediatric PCCs in performing those roles, including ■■ Developmental-behavioral pediatricians ■■ Specialists in neurodevelopmental disabilities
Previous Page Next Page